RITUXIMAB-ABBS
Manufacturer: Cephalon, Inc.
Score: 144.0
Truxima (rituximab-abbs) is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. It is used for the treatment of adult patients with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The most common adverse reactions were infusion-related reactions, fever, lymphopenia, chills, infection, and asthenia. Important safety information includes fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy (PML).
Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy (PML)
No dose adjustment is necessary for patients with renal or hepatic impairment
375 mg/m2 as an intravenous infusion
Not established
375 mg/m2 in the first cycle and 500 mg/m2 in cycles 2-6
Not established
Two 1000 mg intravenous infusions separated by 2 weeks
Not established
375 mg/m2 once weekly for 4 weeks
Not established